A handful of U.S. Senators, Chuck Grassley (R-Iowa); Senator Amy Klobuchar (D-Minn.); Senator Richard Blumenthal (D-Conn.); Senator Patrick Leahy (D-Vt.); and Senator Ron Johnson (R-Wis.), recently wrote to the U.S. Food and Drug Administration (FDA) expressing concerns that the agency has helped to stifle competition to Mylan’s EpiPen. Learn more about the decisions in question here. (Source: Ed Silverman, PHARMALOT, 8/25/16)
You are here: / / Does the FDA Share Blame Over EpiPen Price Gouging?